Trastuzumab and its radioimmunoconjugates in treatment of cancer

Sterjova, Marija and Apostolova, Paulina and Dzodic, Predrag and Smilkov, Katarina and Gjorgieva Ackova, Darinka and Janevik-Ivanovska, Emilija (2016) Trastuzumab and its radioimmunoconjugates in treatment of cancer. Macedonian Pharmaceutical Bulletin, 62. pp. 417-418. ISSN 1409 - 8695

[thumbnail of Farmacevtski kongres.pdf]
Farmacevtski kongres.pdf

Download (383kB) | Preview
[thumbnail of Contents.pdf]

Download (326kB) | Preview
[thumbnail of Section 4.pdf]
Section 4.pdf

Download (1MB) | Preview


Monoclonal antibodies are new type of targeted anticancer therapy, which achieve specificity, selectivity and localization in tumor cells. There are many naked antibodies and immunoconjugates commercially approved for different types of cancer (Mehren et al., 2003). In order to improve specificity and selectivity of cytotoxic drugs and toxins, monoclonal antibodies are used for formulation of immunoconjugates. Many efforts are done to develop stable immunoconjugates of trastuzumab with various drugs, toxins and radioisotopes to improve the general conditions of the patients (Sharkey and Goldenberg, 2006). The aim of this paper is to focus on current achievements in the formulation of radioimmunoconjugates of HER2-targeting trastuzumab.

Item Type: Article
Subjects: Medical and Health Sciences > Other medical sciences
Divisions: Faculty of Medical Science
Depositing User: Marija Arev
Date Deposited: 13 Sep 2016 10:01
Last Modified: 06 Mar 2018 10:35

Actions (login required)

View Item View Item